Search
Virax chairman Wayne Millen.

Virax takeover clinches anti-cancer drug

Virax Holdings has agreed to acquire Pathway Oncology in a reverse takeover which will see the Australia-listed company gain control of a global licence for emerging anti-cancer technology.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Share Transactions

26/07/16
$4k Bought
30/06/16
$13k Issued
30/06/16
$0 Issued
Total value as at the date of the transaction
Source: Morningstar

BNiQ Disclaimer